Tag Archives: John Newman

Analysts’ Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (NASDAQ: IMGN), SAGE Therapeutics (NASDAQ: SAGE) and Homology Medicines (NASDAQ: FIXX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ImmunoGen (IMGN – Research Report), SAGE Therapeutics (SAGE – Research Report) and Homology Medicines (FIXX – Research Report). ImmunoGen (IMGN) In a report released yesterday,

Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (NASDAQ: OCUP), Mirati Therapeutics (NASDAQ: MRTX) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocuphire Pharma (OCUP – Research Report), Mirati Therapeutics (MRTX – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report) with bullish sentiments.

Analysts’ Top Healthcare Picks: Regeneron (REGN), Ascendis Pharma (ASND)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Ascendis Pharma (ASND – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments. Regeneron

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Aptose Biosciences (APTO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Aptose Biosciences (APTO – Research Report) and scPharmaceuticals (SCPH – Research Report) with bullish sentiments. Regeneron (REGN)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sesen Bio (NASDAQ: SESN) and Amphastar Pharmaceuticals (NASDAQ: AMPH)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sesen Bio (SESN – Research Report) and Amphastar Pharmaceuticals (AMPH – Research Report). Sesen Bio (SESN) Canaccord Genuity analyst John Newman maintained a

Histogen (HSTO) Has a New Rating from Canaccord Genuity

Histogen (HSTO – Research Report) received a Buy rating and a $5.00 price target from Canaccord Genuity analyst John Newman today. The company’s shares closed last Wednesday at $1.17, close to its 52-week low of $0.75. According to TipRanks.com, Newman